Study Funding. The Sponsor shall provide funding for the Study and as such there are no required payments from Grand River Hospital. Grand River Hospital’s study compensation is based on the Grand River Hospital Health Records Research Fee Schedule outlined in Appendix B of this Agreement. This Agreement shall be governed by, and shall be interpreted, construed and enforced, in accordance with the laws of the Province of Ontario and the laws of the country of Canada applicable thereto. Any legal action, claim or other legal proceeding commenced by one Party hereto against another Party, arising out of this Agreement, shall be commenced in the courts of the Province of Ontario, Canada; and the Parties shall attorn to such jurisdiction. The Study Team agree to conduct the Study in accordance with applicable laws and regulations of the Province of Ontario, Canada, including but not limited to those laws and regulations which deal with the privacy of personal health information and personal information, freedom of information as well as in accordance with Grand River Hospital’s Privacy, Confidentiality and Security Policy. The Study Team will respect the Study Participants’ privacy in accordance with the Ontario Personal Health Information Protection Act (PHIPA), and with any other applicable privacy legislation throughout the conduct of the Study. All Source data will be anonymously mapped and analysed through data aggregation techniques. Except as otherwise required by law or regulation, no party shall release or distribute confidential information or any materials or information containing the name of or any other identifiable Study Participant information without prior written approval from Grand River Hospital, and such approval shall not be unreasonably withheld. In the event that information is required to be disclosed pursuant to law or regulation, the party required to make disclosure shall notify the other to allow that party to assert whatever exclusions or exemptions may be available to it under such law or regulation. The obligations of confidentiality set forth in this Agreement shall survive the termination of this Agreement from the date that the recipient receives the Grand River Hospital confidential information. However confidential information does not include information that is: already known to the party to which it is disclosed and that party can show by written records that it is already known; becomes part of the public domain without breach of this...
Study Funding. (a) Payments to the Institution and Investigator for the performance of Study shall be made by MedImmune through Utrecht, in accordance with Exhibit I, attached to this Agreement (the “Budget and Payment Schedule”). The Institution and Investigator hereby acknowledge and agree that payments due under this Agreement are pass-through payments and that Utrecht shall have no payment obligations hereunder until such time as said payments are received by Utrecht. The compensation and reimbursement described in the Budget will be the only amounts due or payable to the Institution or Investigator for services provided under this Agreement. Each Study budget includes all direct and indirect costs and expenses (including reasonable pass-through costs (without mark-up) as authorized by MedImmune including any applicable overhead of the Institution or Investigator. Each Study budget shall be determined by the Parties through good faith and arms-length bargaining to be the fair market value of the Study in light of the rights granted to Institution and Investigator hereunder and risks and obligations of MedImmune undertaken in connection with the Study. The Study budget shall not be determined in a manner that takes into account the volume or value of any referrals or other business otherwise conducted between the Parties for which payment may be made under any government health care program or otherwise, nor shall it be determined, or any part of the payments made thereunder, in exchange for any explicit or implicit agreement that Institution or Investigator or any other Institution representatives purchase, recommend, prescribe or otherwise arrange for the use of any product of MedImmune or a MedImmune “Affiliate” (which means any business entity that is controlled by or under common control with MedImmune, LLC).
Study Funding. The City will obtain bids, prepare purchase agreement, and obtain City Council approval and budget appropriation for the project within 4 months of the ECA Effective Date.
Study Funding. MAG is the recipient of FY 2018 FHWA Planning Funds as described in the FY 2018 MAG Unified Planning Work Program and in the agreement between MAG and the Arizona Department of Transportation.
Study Funding. In the absence of grant support, each Institution will be responsible for its own Study costs. For clarity, in the absence of grant support, there is no obligation to any Institution to participate in a Study. Grant applications for Study funding may be initiated by the Lead Institution with support from the Members. Budgeting for grant applications should take into account Study costs at all participating Institutions, including the time of the National Coordinator. Grant management for each Study will be the responsibility of the Lead Institution and the Study Principal Investigator, with transfers to other Institutions as appropriate, the modalities of such transfers to be determined in separate fund transfer Agreements or in the Implementing Letters.
Study Funding. The Study shall be funded by the Company in accordance with the budget attached hereto as Appendix C (the "Budget"). The Budget may be amended from time to time upon the written agreement of the Parties.
Study Funding. The Sponsor shall provide funding for the Study and as such there are no required payments from St. Mary’s General Hospital. St. Mary’s General Hospital’s study compensation is based on the St. Mary’s General Hospital Health Records Research Fee Schedule outlined in Appendix B of this Agreement.
Study Funding. The Settling Respondent will let a contract for the Denitrification Pilot Study and will allocate necessary funds for the Denitrification Pilot Study, coordinate equipment installation with the vender, and submit a purchase order to the vendor for delivery and installation of necessary Denitrification Pilot Study equipment. This phase of the Denitrification Pilot Study will be completed within 1 month of the ECA Effective Date.
Study Funding. (a) MedImmune declares, that paymnets listed in the Exhibit I forms 20% of the total budget fo the Study. Payments to the Institution for the performance of Study shall be made by MedImmune through Utrecht, in accordance with Exhibit I, attached to this Agreement (the “Budget and Payment Schedule”). The Institution and Investigator hereby acknowledge and agree that payments due under this Agreement are pass-through payments and that Utrecht shall have no payment obligations hereunder until such time as said payments are received by Utrecht. The compensation and reimbursement described in the Budget will be the only amounts due or payable to the Institution for services provided under this Agreement. Each Study budget includes all direct and indirect costs and expenses (including reasonable pass-through costs (without mark-up) as authorized by MedImmune including any applicable overhead of the Institution or Investigator. Each Study budget shall be determined by the Parties through good faith and arms-length bargaining to be the fair market value of the Study in light of the rights granted to Institution and Investigator hereunder and risks and obligations of MedImmune undertaken in connection with the Study. The Study budget shall not be determined in a manner that takes into account the volume or value of any referrals or other business otherwise conducted between the Parties for which payment may be made under any government health care program or otherwise, nor shall it be determined, or any part of the payments made thereunder, in exchange for any explicit or implicit agreement that Institution or Investigator or any other Institution representatives purchase, recommend, prescribe or otherwise arrange for the use of any product of MedImmune or a MedImmune “Affiliate” (which means any business entity that is controlled by or under common control with MedImmune, LLC).
Study Funding. This is an ISCCM funded study. The ISCCM will fund the PI of the study for the expenses incurred related to software development, secretarial assistance, data analysis and other miscellaneous expenses against actual bills. No funding will be given to other investigators from other centres for contributing the data.
